The Experts below are selected from a list of 61308 Experts worldwide ranked by ideXlab platform
David N Louis - One of the best experts on this subject based on the ideXlab platform.
-
Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human Astrocytomas appear related to malignancy grade.
Journal of Neuropathology and Experimental Neurology, 1999Co-Authors: Jonathan S Silver, Lisa Blazejewski, Masao Matsutani, Andreas Von Deimling, Ryo Nishikawa, David N LouisAbstract:Approximately 30% of human Astrocytomas have been reported to display allelic loss of the long arm of chromosome 22, suggesting the presence of a chromosome 22q Astrocytoma suppressor gene. To define the most likely location for this putative tumor suppressor, we performed deletion mapping on 141 tumors using 16 chromosome 22q microsatellite markers. Allelic loss of 22q was observed in 2/12 (17%) of Astrocytomas, 9/29 (31%) of anaplastic Astrocytomas, and 38/100 (38%) of glioblastomas, consistent with a role for chromosome 22q loss in Astrocytoma progression as well as formation. Twenty-two tumors exhibited allelic loss at every informative locus, consistent with loss of the entire arm of 22q. Twenty-seven tumors showed partial deletions, with one common region of deletion at 22q12.3-q13.1 between markers D22S280 and D22S282, and a second candidate region at 22q13.2 near the marker D22S1170. For the proximal candidate region, the incidence of allelic loss was similar between grades; for the distal locus, the incidence increased with grade, raising the possibility that the distal locus is involved in a later stage of Astrocytoma tumorigenesis.
-
mts1 cdkn2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
-
MTS1/CDKN2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
Andreas Von Deimling - One of the best experts on this subject based on the ideXlab platform.
-
Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human Astrocytomas appear related to malignancy grade.
Journal of Neuropathology and Experimental Neurology, 1999Co-Authors: Jonathan S Silver, Lisa Blazejewski, Masao Matsutani, Andreas Von Deimling, Ryo Nishikawa, David N LouisAbstract:Approximately 30% of human Astrocytomas have been reported to display allelic loss of the long arm of chromosome 22, suggesting the presence of a chromosome 22q Astrocytoma suppressor gene. To define the most likely location for this putative tumor suppressor, we performed deletion mapping on 141 tumors using 16 chromosome 22q microsatellite markers. Allelic loss of 22q was observed in 2/12 (17%) of Astrocytomas, 9/29 (31%) of anaplastic Astrocytomas, and 38/100 (38%) of glioblastomas, consistent with a role for chromosome 22q loss in Astrocytoma progression as well as formation. Twenty-two tumors exhibited allelic loss at every informative locus, consistent with loss of the entire arm of 22q. Twenty-seven tumors showed partial deletions, with one common region of deletion at 22q12.3-q13.1 between markers D22S280 and D22S282, and a second candidate region at 22q13.2 near the marker D22S1170. For the proximal candidate region, the incidence of allelic loss was similar between grades; for the distal locus, the incidence increased with grade, raising the possibility that the distal locus is involved in a later stage of Astrocytoma tumorigenesis.
-
mts1 cdkn2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
-
MTS1/CDKN2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
Keisuke Ueki - One of the best experts on this subject based on the ideXlab platform.
-
mts1 cdkn2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
-
MTS1/CDKN2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
Vijaya Ramesh - One of the best experts on this subject based on the ideXlab platform.
-
mts1 cdkn2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
-
MTS1/CDKN2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
Joni L Rutter - One of the best experts on this subject based on the ideXlab platform.
-
mts1 cdkn2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
-
MTS1/CDKN2 gene mutations are rare in primary human Astrocytomas with allelic loss of chromosome 9p
Human Molecular Genetics, 1994Co-Authors: Keisuke Ueki, Mari Paz Rubio, Vijaya Ramesh, Katia M Correa, Joni L Rutter, Andreas Von Deimling, Alan J Buckler, James F. Gusella, David N LouisAbstract:: Human Astrocytomas frequently have allelic losses of chromosome 9p, suggesting the presence of a 9p Astrocytoma tumor suppressor gene. The MTS1 (or CDKN2) gene on chromosome 9p encodes a cell-cycle regulator and is deleted in approximately 80% of Astrocytoma cell lines. To determine whether MTS1 is the tumor suppressor gene involved in human Astrocytoma formation in vivo, we have analyzed chromosome 9p allelic loss and the MTS1 gene in 30 primary Astrocytomas. Deletion mapping demonstrated 15 cases with allelic loss of chromosome 9p, with all losses either flanking or involving the MTS1 gene. Direct analysis of the MTS1 gene, however, revealed only a single missense mutation in a high-grade tumor that had lost the second allele. The low frequency of MTS1 mutations in primary Astrocytomas with allelic 9p loss suggests that MTS1 may be more important for in vitro than in vivo Astrocytoma growth, and that another 9p tumor suppressor gene may be involved in Astrocytoma formation in vivo. Analysis of the MTS1 gene also demonstrated two intragenic polymorphisms, one in exon 2 and one in the 3' untranslated region, that can be used to assay allelic loss directly at MTS1.
